ARTLWArtelo Biosciences, Inc.
Partial data—Mkt Cap: —P/E: —308d ago
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13,…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.88M $
Revenue/Share—
Last Price—
Fiscal Year End—
MR Quarter—
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.02
EPS (TTM)-1.43
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE1012.50%
ROA-459.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.52M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-7.48M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.53
Current Ratio11.36
Quick Ratio10.55
Book Value/Sh-0.3530 USD
Cash/Share2.357 USD
Dividends
Fwd Div Rate—
Trail. Div Rate—
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.33M
Float3.20M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta1.25
S&P 52W Chg15.96%
Avg Vol (30d)—
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—